Targeted metabolomic analyses of cellular models of pelizaeus-merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction by Wood, Paul L et al.
RESEARCH Open Access
Targeted metabolomic analyses of cellular
models of pelizaeus-merzbacher disease reveal
plasmalogen and myo-inositol solute carrier
dysfunction
Paul L Wood
*, Tara Smith, Lindsay Pelzer and Dayan B Goodenowe
Abstract
Background: Leukodystrophies are devastating diseases characterized by dys- and hypo-myelination. While there
are a number of histological and imaging studies of these disorders, there are limited biochemical data available.
We undertook targeted lipidomic analyses of Pelizaeus-Merzbacher disease (PMD) fibroblasts, PMD lymphocytes,
and 158JP oligodendrocytes, a murine model of PMD, to define the lipid changes in these cell models. Further
targeted metabolomics analyses were conducted to obtain a preliminary evaluation of the metabolic
consequences of lipid changes and gene mutations in these cell models.
Results: In both PMD fibroblasts and lymphocytes, and 158JP oligodendrocytes, ethanolamine plasmalogens were
significantly decreased. Labeling studies with 158JP oligodendrocytes further demonstrated a decreased rate of
lipid remodeling at sn-2. Targeted metabolomics analyses of these cells revealed dramatic increases in cellular
levels of myo-inositol. Further uptake studies demonstrated increased rates of myo-inositol uptake by PMD
lymphocytes.
Conclusions: Our data demonstrating PlsEtn decrements, support previous studies indicating leukodystrophy cells
possess significant peroxisomal deficits. Our data for the first time also demonstrate that decrements in
peroxisomal function coupled with the PLP1 gene defects of PMD, result in changes in the function of membrane
myo-inositol solute carriers resulting in dramatic increases in cellular myo-inositol levels.
Keywords: leukodystrophy, Pelizaeus-Merzbacher disease, fibroblasts, lymphocytes, 158JP oligodendrocytes, plasma-
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Background
The leukodystrophies include a heterogeneous group of
both childhood and late onset genetic diseases that pri-
marily result in dys- or hypo-myelination [1,2]. Further-
more, these disorders are highly misdiagnosed such that
disease incidence is much greater than previously
thought [3]. Neuroimaging has significantly improved
the ability to detect the CNS deficits in these disorders.
However, there is limited biochemical knowledge of the
underlying disease processes. Therefore, we undertook a
targeted lipidomics analysis of the established
peroxisomal deficits in PMD fibroblasts [4,5], PMD lym-
phocytes, and 158 JP oligodendrocytes [6], all of which
demonstrate a proteolipid protein-1 (PLP1) mutation. A
targeted metabolomics analysis of the consequences of
PLP1 mutations on cellular metabolism also was
conducted.
Materials and Methods
Cell Culture
The following cell lines were analyzed: two murine oli-
godendrocytes cell lines, 158N (normal) and the PLP1
mutant 158JP (Jimpy) (a generous gift from Dr. S Ghan-
dour); control human lymphocytes (Coriell GM00131
and GM02184); human PMD lymphocytes (Coriell
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and ATCC CRL-2076) and human PMD fibroblasts
(Coriell GM09546). All fibroblast cell lines and oligo-
dendrocytes were cultured (10 cm
2 plates) in DMEM:
F12 (Mediatech) supplemented with 15% FBS (Invitro-
gen) and 1% antibiotic/antimycotic (Invitrogen). Lym-
phocyte cell lines were suspension cultures (25 ml
flasks) in RPMI 1640 (Hyclone) supplemented with 10%
FBS and 1% antibiotic/antimycotic. All cells were grown
at 37°C in a 5% CO2 incubator. Fibroblast cells and oli-
godendrocytes were harvested when plates reached con-
fluence using a cocktail of Versene and TryPLe express
(2:1; Gibco). For all cells the pellet (1280 xg) was
washed twice with phosphate buffered saline (PBS) and
the stored at -80°C for subsequent analyses.
RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated from confluent T-25 flasks of
GM00131, GM02184 and GM09545 using the RNeasy
Mini Kit (Qiagen) as per the manufacture’sp r o t o c o l( n
= 4). Quantification of RNA was performed by optical
density with the NanoVue spectrophotometer (GE
Healthcare Life Sciences). Reverse transcription reac-
tions were performed on 1 μgR N Au s i n gt h eq S c r i p t
cDNA SuperMix (Quanta Biosciences). Each sample was
analyzed to determine expression of the housekeeping
gene b-actin (sense-5’ agccatgtacgtagccatcc 3’; antisense-
5’ ctctcagctgtggtggtgaa 3’)a sw e l la sS M I T 1( s e n s e - 5 ’
gctacgagctggctttaatcct 3’; antisense-5’ tttactcaggtgctggag-
gagaa 3’)[ 7 ]a n dS M I T 2( s e n s e - 5 ’ gcctccacagttagatcccc
3’; antisense-5’ cagaactagcaccgcgatgt 3’) [8]. Specificity of
each primer set was determined by analysis of the disso-
ciation curve. Quantitative real-time PCR was carried
out in triplicate using the Fast SYBR Green Master Mix
(Applied Biosystems) on the StepOne Plus Real-Time
PCR System (Applied Biosystems). Thermocycling con-
ditions were: 95°C for 20s followed by 40 cycles of 95°C
for 3s and 60°C for 30s.
Plasmalogen Synthesis
To monitor plasmalogen synthesis in 158N and 158JP
oligodendrocytes, cells were incubated with 100 uM
PPI-1038 for 72 hr and incorporation into cellular plas-
malogens measured. PPI-1038 is an ether lipid plasmalo-
gen precursor with a [
13C3]glycerol backbone, a [
13C16]
palmitic ether linkage at sn-1, a [
13C3]DHA acyl linkage
at sn-2, and a lipoic acid acyl linkage at sn-3 to stabilize
the precursor.
Plasmalogen Analyses
For plasmalogen analyses, cells were sonicated in 1 mL
of PBS + 0.5 mL methanol. Next, 2 mL tert-butylmethy-
lether were added and the samples capped and shaken
(1400 rpm) for 10 min at room temperature. The
samples were then centrifuged for 8 min in a clinical
centrifuge and 1 ml of the upper organic layer isolated
for LC-MS/MS analyses of endogenous and labeled
ethanolamine plasmalogens as reported previously [9].
Myo-Inositol Analyses
Harvested cells were sonicated in 1.2 ml of acetonitrile:
MeOH:formic acid (800:200:2.4) containing [
2H6]myo-
inositol internal standard. These cell lysates were centri-
fuged at 4°C and 25,000xg for 30 min. Two 400 μL ali-
quots of the supernatant were transferred to 1.5 ml
screw top microtubes and dried in a Savant centrifugal
evaporator. For myo-inositol analysis, timethylsilylation
of the samples was conducted at 80°C for 1 hr with 100
μL acetonitrile and 100 μL of N, O-bis(trimethylsilyl)tri-
fluoroacetamide and TMCS (10/1). The TMS derivatives
were analyzed by GC-MS with the [MH]
+ cations of
613.2 and 619.2 monitored for myo-inositol and [
2H6]
myo-inositol, respectively. GC-MS analyses were per-
formed with an Agilent 7890A GC and an Agilent
5975C mass analyzer, with ammonia as the reagent gas.
The GC column was a 30 m HP-5MS (0.25 mm ID;
0.25 μm film).
Myo-Inositol Uptake
Cells were incubated for 0.5, 1, 2, and 3 hours with
HBSS-HEPES, containing MEM vitamins and 200 uM
[
2H6]myo-inositol. At the end of the incubation cells
were washed with ice-cold PBS and processed as
described above. Intracellular [
2H6]myo-inositol was
monitored as described above using [
13C6]glucose as the
internal standard.
Data Analyses
Data are presented as mean ± SEM for groups of five to
six 10 cm
2 plates or 25 ml flasks. Since standards are
not available for the lipidomics analysis of plasmalogens,
these were normalized to the housekeeping metabolite
PtdEtn 16:0/18:0. For myo-inositol analyses, concentra-
tions were expressed on a per mg protein basis [10].
GC-MS analyses were performed using 5 point standard
curves (reference standards at 0.2 to 10 times the stable
isotope internal standard). Data were analyzed by t-test.
Results
Ethanolamine Plasmalogens
Peroxisomal deficiency is known to result in plasmalo-
gen deficiency [13].
In the case of 158JP oligodendrocytes, both white mat-
ter ethanolamine plasmalogens (PlsEtn 16:0/18:1; 16:0/
18:2, 18:0/18:1; 18:0:18:2) and gray matter PlsEtn(16:0/
20:4, 16:0/22:6, 18:0/20:4, 18:0/22:6) were decreased by
50 to 75% (Figure 1). Plasmalogen decrements in PMD
fibroblasts were not global, being restricted to
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were 10 to 30% (Figure 1). Plasmalogen decrements in
PMD lymphocytes also were not global, being restricted
to plasmalogens with 18:1 or 18:2 at sn-2. These
decreases were 14 to 56% (Figure 1).
Ethanolamine Plasmalogen Synthesis
Incorporation of intact labeled PPI-1038 (i.e. P-G-D =
[
13C16]Palmitate-[
13C3]Glycerol-[
13C3]-DHA) into the
target plasmalogen (P-G-D PlsEtn 16:0/22:6) was not
significantly different between 158 N and 158 JP oligo-
dendrocytes (Figure 2). However, lipid remodeling,
namely deacylation/reacylation at sn-2 was significantly
decreased (Figure 2).
Probe Targeted Metabolomics Study
Targeted metabolomics analysis of cells was undertaken
utilizing four GC-MS panels that assay over 100 meta-
bolic intermediates in amino acid, nucleotide, alcohol,
sugar, polyol, fatty acid, and organic acid pathways. The
most dramatic alterations observed in this probe study
were increases in cellular myo-inositol levels.
Myo-Inositol Co-Transporters
Myo-inositol levels were significantly elevated in 158JP
oligodendrocytes and in PMD fibroblasts and lympho-
cytes (Table 1), all of which possess PLP mutations.
Studies of [
2H6]myo-inositol uptake demonstrated that
changes in cellular levels were reflected by 2.3-fold
increases in the uptake rate of myo-inositol in PMD
lymphocytes (Figure 3). PCR analyses of lymphocytes
demonstrated the presence of both SMIT1 and SMIT2
but no difference in expression between PMD and con-
trol cells.
Discussion
The role(s) of peroxisomal dysfunction in leukodystro-
phies remains to be clearly defined. Both endoplasmic
reticulum (ER) dysfunction (due to accumulation of
mis-folded proteins in the ER of PMD cells [11-13]) and
peroxisomal dysfunction may be involved in the plasma-
logen decrements monitored in this study since both of
these cellular compartments are essential for plasmalo-
gen synthesis. Addition of the phosphoethanolamine
group at sn-3 [EC 3.1.3.4] of the glycerol backbone and
the desaturation of the ether linked fatty acid at sn-1
[EC 1.14.99.19], both occur in the ER [11]. In addition,
the many complex interactions between peroxisomes,
mitochondria and the ER [14] may be important in the
biochemical changes monitored in leukodystrophy cells.
This dysfunction is further reflected by the decreased
lipid remodeling of plasmalogens via deacylation and
reacylation at sn-2. Such decrements in lipid remodeling
will also have negative effects on cellular signaling [6].
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Figure 1 Ethanolamine plasmalogen levels in 158JP oligodendrocytes and Pelizaeus- Merzbacher disease (PMD) fibroblasts and
lymphocytes. N = 6. *, p < 0.01 vs. control. Mean ± SEM.
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plasmalogens we measured in PMD fibroblasts are con-
sistent with the decreases in white matter [15] and neu-
ronal loss [16] in PMD patients. It is not unexpected
that alterations in membrane plasmalogens, which
represent 85% of the myelin lipid pool, and in PLP,
which represents 50% of the myelin protein pool, might
alter membrane transporter function in this complex
disease. Prior research has demonstrated that plasmalo-
gen deficiency [17-19] and PLP mutations [20] result in
decreased cellular export of cholesterol. Negative effects
on other transporters in PMD are to be anticipated as a
result of these complex changes in membrane ultra-
structure. Previous NMR data have demonstrated
increases in PMD brain myo-inositol [15]. Our data in
PMD fibroblasts and lymphocytes and in 158JP oligo-
dendrocytes support these findings and demonstrate
that increased myo-inositol uptake is responsible for
these changes. In toto, these data suggest that changes
in membrane plasmalogens and/or membrane PLP lead
to altered function of sodium/myo-inositol transporters
SMIT1 and SMIT2 [7,8,21,22], resulting in cellular accu-
mulation of myo-inositol.
In addition to PMD [15], in vivo magnetic resonance
spectroscopy studies have demonstrated increases in
brain myo-inositol in a number of other leukodystro-
phies including Krabbe disease [23], infantile Alexander
disease [24], metachromatic leukodystrophy [25], adult
X-linked adrenoleukodystrophy [26], and childhood X-
linked adrenoleukodystrophy [27]. In childhood X-linked
adrenoleukodystrophy [27], increases in myo-inositol
appear to coincide with the onset of hypomyelination.
Myo-inositol accumulation has also been implicated in
the etiology of peripheral neuropathies [28]. Our data,
combined with the rich publication record of magnetic
resonance spectroscopy studies suggest that elevated
myo-inositol levels in brain white matter tracts may be a
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Figure 2 Incorporation of PPI-1038 (100 μM; 72 hr) into the 16:0/22:6, 18:0/22:6 and 18:1/22:6 plasmalogens of 158N and 158JP
oligodendrocytes.N=5 .P=[
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13C3]glycerol; D = [
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Table 1 Myo-Inositol levels in 158JP oligodendrocytes,
PMD fibroblasts and PMD lymphocytes
Cells Myo-Inositol (-fold control)
158JP oligodendrocytes 8.7 ± 0.78
PMD Fibroblasts 6.8 ± 0.55
PMD Lymphocytes 1.9 ± 0.10
N = 5 (repeated 3 times); all increases are significant (p < 0.01)
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osmotic pressure resulting from altered myo-inositol
transport [29] could represent an initiating event in the
cell death of oligodendrocytes as further reflected by the
increased osmotic fragility of myelin lamellae in PLP-
null mice [30].
In summary, PLP mutations are known to result in
dysfunction of the complex organelle interplay of per-
oxisomes, mitochondria and ER thereby affecting traf-
ficking of critical membrane proteins and phospholipids.
While it is well established that these aberrant processes
can result in dys- and hypo-myelination, our data are
the first to demonstrate the dramatic effects on myo-
inositol solute carriers which also may be responsible
for myelin dysfunction.
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